Related Experiment Video
Updated: Dec 15, 2025
09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
22.1K
Neurological update: neuroimaging in dementia
1Department of Neurosciences, University of Cambridge, Cambridge, UK. tr332@medschl.cam.ac.uk.
Journal of Neurology
|July 9, 2020
Summary
Recent advances in neuroimaging offer new ways to diagnose dementia subtypes, predict prognosis, and monitor pathology. Quantitative susceptibility imaging shows promise as a sensitive biomarker for neurodegenerative diseases.
Area of Science:
- Neurology
- Radiology
- Biomedical Engineering
Background:
- Neuroimaging has significantly advanced dementia research.
- Current methods aid in diagnosis, prognosis, and pathology monitoring.
Purpose of the Study:
- To review recent updates in dementia understanding through neuroimaging.
- To highlight novel techniques and their clinical translation challenges.
Main Methods:
- Review of structural imaging, PET, connectivity analyses.
- Application of big data and artificial intelligence in neuroimaging.
- Focus on quantitative susceptibility imaging (QSI).
Main Results:
- Neuroimaging enables in vivo examination of neuropathology.
- Development of biomarkers for neurodegeneration and clinical trials.
- QSI identified as a potential sensitive biomarker for neurodegenerative diseases.
Conclusions:
- Neuroimaging offers powerful tools for dementia research and clinical applications.
- Challenges remain in standardizing novel techniques and regulatory approval.
- Clinician leadership is crucial for overcoming translation obstacles.
More Related Videos
Related Concept Videos
01:14Brain Imaging
555
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
555
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:30Dementia
417
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
417
01:22Alzheimer's Disease: Treatment
659
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
659